Topotarget is a Scandinavian-based oncology late-stage clinical development company. Topotarget aims at improving the quality of and prolonging the lives of cancer patients by offering novel, safe, and effective cancer drugs. Our lead compound belinostat is a Histone Deacetylases (HDAC) inhibitor that is being tested in a number of clinical trials.